Imperial College London's saRNA Vaccine - COVAC1

Hae kokoteksti
Series

Potential long-term health effects of a SARS-CoV-2 infection

Hae kokoteksti
Series

Interferon-α2b as a therapy for COVID-19

Hae kokoteksti
Series

The COVID-19 coronavirus outbreak October 2020 update /

Hae kokoteksti
Series

Presence and function of SARS-CoV-2-specific T-cells in recovered patients and healthy volunteers

Hae kokoteksti
Series

Rheumatic diseases and COVID-19

Hae kokoteksti
Series

The development of therapeutic antibodies against oncogenic antigens

Hae kokoteksti
Series

The cardiovascular complications of SARS-CoV-2 infection

Hae kokoteksti
Series

Medical wearable devices for tracking symptoms of COVID-19

Hae kokoteksti
Series

Risk of re-emergence of COVID-19 after exit from lockdown

Hae kokoteksti
Series

The evolutionary origin of SARS-CoV-2

Hae kokoteksti
Series

Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge

Hae kokoteksti
Series

Approaches for elucidating genetic susceptibility to SARS-CoV-2

Hae kokoteksti
Series

The immune system response to the SARS-CoV-2 virus July 2020 update /

Hae kokoteksti
Series

The impact of COVID-19 in the elderly and in care homes

Hae kokoteksti
Series

Human challenge trials for vaccines against COVID-19

Hae kokoteksti
Series

Addressing required changes in the UK health system for the health and wellbeing for individuals with learning (intellectual) disabilities

Hae kokoteksti

The development of SARS-CoV-2 vaccines

Hae kokoteksti
Series

Convalescent plasma therapy as a treatment for COVID-19

Hae kokoteksti
Series

Remdesivir COVID-19 clinical trial

Hae kokoteksti
Series